Study guide
2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment
Key Takeaways Explain This Topic AI
Lipoproteins consist of a hydrophobic nonpolar lipid core (triglycerides and cholesteryl esters) surrounded by an amphipathic monolayer of phospholipids, free cholesterol, and specific apolipoproteins.
Apolipoprotein B-100 is the structural marker and ligand for atherogenic lipoproteins (VLDL, IDL, LDL), whereas Apo A-I is the primary structural apolipoprotein and LCAT activator of cardioprotective HDL.
The Friedewald formula calculates LDL-C as Total Cholesterol − HDL-C − ( Triglycerides / 5 ) \text{Total Cholesterol} - \text{HDL-C} - (\text{Triglycerides}/5) Total Cholesterol − HDL-C − ( Triglycerides /5 ) in mg/dL, but is strictly invalid when serum triglycerides exceed 400 mg/dL 400\text{ mg/dL} 400 mg/dL ( 4.52 mmol/L 4.52\text{ mmol/L} 4.52 mmol/L ) or when chylomicrons or dysbetalipoproteins are present.
According to NCEP ATP III guidelines, optimal lipid cutoffs are LDL-C < 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL , HDL-C ≥ 60 mg/dL \ge 60\text{ mg/dL} ≥ 60 mg/dL (protective), Total Cholesterol < 200 mg/dL < 200\text{ mg/dL} < 200 mg/dL , and Triglycerides < 150 mg/dL < 150\text{ mg/dL} < 150 mg/dL ; triglycerides exceeding 1000 mg/dL 1000\text{ mg/dL} 1000 mg/dL present an imminent threat of acute pancreatitis.
Lipoprotein(a) and high-sensitivity C-reactive protein (hs-CRP) serve as independent cardiovascular risk stratification biomarkers beyond routine lipid panel calculations.
Last updated: October 2026
Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment
Lipids are water-insoluble biological organic molecules that play essential structural, metabolic, and signaling roles in human physiology. Because lipids are insoluble in aqueous solutions, they are transported throughout the vascular compartment packaged within macromolecular micellar assemblies termed lipoproteins . Derangements in lipid and lipoprotein metabolism represent the central pathophysiological basis for atherosclerotic cardiovascular disease (ASCVD). Medical technologists must master lipid biochemistry, apolipoprotein functions, analytical calculations, and diagnostic dyslipidemia classifications.
1. Lipid Chemistry and Biological Classification
Fatty Acids: Linear hydrocarbon chains terminating in a polar carboxyl group. Classified by hydrocarbon chain length and degree of unsaturation (saturated without double bonds; monounsaturated with one double bond; polyunsaturated with two or more double bonds). Essential fatty acids (linoleic and α \alpha α -linolenic acids) must be obtained from dietary sources.
Triglycerides (Triacylglycerols): Composed of one molecule of glycerol esterified with three fatty acid molecules. Represent the primary storage form of metabolic energy in adipose tissue ( > 90 % >90\% > 90% ) and the principal constituent of exogenous dietary fat.
Cholesterol: A 27-carbon alicyclic steroid alcohol containing a cyclopentanoperhydrophenanthrene four-ring nucleus. Essential structural component of eukaryotic cell membranes, determining membrane fluidity and lipid raft integrity. Serves as the biochemical precursor for bile acids, vitamin D, and all steroid hormones (adrenocortical glucocorticoids, mineralocorticoids, and gonadal sex steroids). In circulating plasma, cholesterol exists in two distinct pools:
Free (Unesterified) Cholesterol (~30%): Amphipathic, with its polar 3 β 3\beta 3 β -hydroxyl group positioned on the external monolayer of lipoproteins.
Cholesteryl Esters (~70%): Hydrophobic nonpolar core lipids, formed when free cholesterol is esterified at carbon-3 with a fatty acid via the enzyme Lecithin-Cholesterol Acyltransferase (LCAT) in plasma or Acyl-CoA:Cholesterol Acyltransferase (ACAT) intracellularly.
Phospholipids: Amphipathic diglycerides containing a glycerol (or sphingosine) backbone, two hydrophobic fatty acid chains, and a polar hydrophilic head group esterified with phosphoric acid and an organic base (e.g., choline forming phosphatidylcholine / lecithin; ethanolamine forming phosphatidylethanolamine; sphingomyelin). Constitute the outer amphipathic monolayer of lipoproteins and biological membranes.
2. Lipoprotein Architecture, Classes, and Electrophoretic Mobility
Lipoproteins are spherical pseudomicellar particles containing a neutral hydrophobic core of triglycerides and cholesteryl esters surrounded by an amphipathic surface monolayer of phospholipids, unesterified free cholesterol, and apolipoproteins.
Physical and Electrophoretic Properties
Under preparative ultracentrifugation, lipoproteins separate based on hydrated density (inversely related to lipid content and directly related to protein content). On agarose gel electrophoresis in barbital buffer at pH 8.6 \text{pH } 8.6 pH 8.6 , lipoproteins migrate according to net surface charge.
Lipoprotein Class Density (g/mL) Diameter (nm) Primary Lipid Component Major Apolipoproteins Electrophoretic Mobility (pH 8.6) Standing Plasma Appearance (4°C)
Chylomicrons < 0.95 < 0.95 < 0.95 75 − 1200 75 - 1200 75 − 1200 Exogenous Triglycerides ( 85 − 90 % 85 - 90\% 85 − 90% ) Apo B-48, Apo A-I, Apo C-II, Apo E Remains at Origin Floating creamy top layer over clear infranate
VLDL 0.950 − 1.006 0.950 - 1.006 0.950 − 1.006 30 − 80 30 - 80 30 − 80 Endogenous Triglycerides ( 50 − 65 % 50 - 65\% 50 − 65% ) Apo B-100, Apo C-II, Apo E Pre- β \beta β (Alpha-2 zone) Turbid / opalescent throughout; no floating layer
IDL 1.006 − 1.019 1.006 - 1.019 1.006 − 1.019 25 − 35 25 - 35 25 − 35 Cholesteryl Esters & Triglycerides Apo B-100, Apo E Broad- β \beta β (Slow pre- β \beta β ) Clear to faintly turbid
LDL 1.019 − 1.063 1.019 - 1.063 1.019 − 1.063 18 − 25 18 - 25 18 − 25 Cholesteryl Esters ( 50 % ~50\% 50% ) Apo B-100 β \beta β (Beta zone) Clear; faint orange-yellow tint
HDL 1.063 − 1.210 1.063 - 1.210 1.063 − 1.210 5 − 12 5 - 12 5 − 12 Protein ( 50 % ~50\% 50% ) & Phospholipids Apo A-I, Apo A-II, Apo C-II α \alpha α (Alpha-1 zone, fastest) Completely clear
3. Apolipoproteins and Reverse Cholesterol Transport
Apolipoproteins are the specialized protein moieties embedded on the lipoprotein surface. They maintain structural integrity, serve as ligands for cell-surface endocytic receptors, and act as essential activators or inhibitors of regulatory vascular enzymes.
Functional Spectrum of Major Apolipoproteins
Apolipoprotein A-I (Apo A-I): The major structural protein of HDL ( 70 % ~70\% 70% of HDL protein). Serves as the definitive physiological activator of LCAT . Clinically quantified as an objective index of anti-atherogenic, cardioprotective capacity.
Apolipoprotein B-48 (Apo B-48): Synthesized exclusively by mucosal enterocytes of the small intestine via post-transcriptional RNA editing of Apo B mRNA (introducing a premature stop codon, yielding 48% of the full-length protein). Lacks the LDL receptor-binding domain. Serves as the obligate structural scaffold for dietary chylomicrons .
Apolipoprotein B-100 (Apo B-100): Synthesized in hepatocytes as the full-length 550 kDa protein. Present on VLDL, IDL, and LDL . Functions as the critical recognition ligand for the hepatic LDL receptor (Apo B/E receptor) . Because each atherogenic particle contains exactly one molecule of Apo B-100, total plasma Apo B-100 measurement reflects the absolute particle number of circulating atherogenic lipoproteins.
Apolipoprotein C-II (Apo C-II): Essential physiological cofactor and activator of endothelial Lipoprotein Lipase (LPL) . In circulating capillaries of adipose tissue and muscle, LPL hydrolyzes core triglycerides in chylomicrons and VLDL to release free fatty acids and glycerol. Hereditary deficiency of Apo C-II leads to severe hyperchylomicronemia.
Apolipoprotein C-III (Apo C-III): Inhibits lipoprotein lipase and hepatic uptake of remnant lipoproteins; elevated levels correlate with hypertriglyceridemia.
Apolipoprotein E (Apo E): High-affinity ligand for the hepatic remnant receptor (LDL receptor-related protein, LRP) and the LDL receptor, mediating rapid endocytosis of chylomicron remnants and IDL. Polymorphic with three major alleles: ϵ 2 \epsilon 2 ϵ 2 , ϵ 3 \epsilon 3 ϵ 3 , and ϵ 4 \epsilon 4 ϵ 4 :
Apo E2: Defective binding to LDL receptors. Homozygosity ( Apo E2/E2 \text{Apo E2/E2} Apo E2/E2 ) produces Type III Familial Dysbetalipoproteinemia .
Apo E4: Associated with elevated plasma LDL cholesterol and represents a major genetic risk factor for late-onset Alzheimer's disease .
Reverse Cholesterol Transport (RCT)
Reverse cholesterol transport is the physiological pathway by which excess unesterified cholesterol is extracted from peripheral cells (including arterial wall macrophage foam cells) and routed to the liver for biliary excretion.
Efflux: Cellular free cholesterol is pumped across the macrophage plasma membrane via ABCA1 (ATP-Binding Cassette transporter A1) to lipid-poor Apo A-I, generating nascent pre- β \beta β HDL. Mature HDL receives additional cholesterol via ABCG1 .
Esterification: LCAT (activated by Apo A-I) transfers a fatty acyl group from phosphatidylcholine to free cholesterol, generating hydrophobic cholesteryl esters that sequester into the particle core, converting discoidal HDL into spherical mature HDL 3 \text{HDL}_3 HDL 3 and HDL 2 \text{HDL}_2 HDL 2 .
Hepatic Clearance: Cholesteryl esters are delivered to the liver either directly through binding to hepatic Scavenger Receptor Class B Type I (SR-BI) or indirectly via Cholesteryl Ester Transfer Protein (CETP) , which exchanges HDL cholesteryl esters for triglyceride molecules from VLDL and LDL.
4. Independent and Emerging Cardiovascular Risk Biomarkers
Lipoprotein(a) [Lp(a)]: An LDL-like particle in which apolipoprotein B-100 is covalently linked by a disulfide bond to the carbohydrate-rich glycoprotein apolipoprotein(a) . Apo(a) exhibits high structural homology to plasminogen , containing multiple kringle-IV repeats. It competitively inhibits plasminogen binding to fibrin, blocking tissue plasminogen activator (tPA)-mediated plasmin generation and blunting fibrinolysis while simultaneously promoting atherogenesis. Plasma Lp(a) levels are > 90 % >90\% > 90% genetically determined, highly refractory to lifestyle or statin therapy, and represent an independent cardiovascular risk factor.
High-Sensitivity C-Reactive Protein (hs-CRP): An acute-phase pentraxin synthesized by hepatocytes under interleukin-6 stimulation. In the absence of overt systemic infection or trauma, baseline hs-CRP reflects low-grade chronic vascular endothelial inflammation and atherosclerotic plaque instability:
- Low Risk: < 1.0 mg/L < 1.0\text{ mg/L} < 1.0 mg/L
- Average Risk: 1.0 to 3.0 mg/L 1.0\text{ to }3.0\text{ mg/L} 1.0 to 3.0 mg/L
High Cardiovascular Risk: > 3.0 mg/L > 3.0\text{ mg/L} > 3.0 mg/L (Note: hs-CRP values > 10.0 mg/L > 10.0\text{ mg/L} > 10.0 mg/L indicate acute systemic infection, tissue injury, or autoimmune flares, invalidating cardiovascular risk assessment).
5. Specimen Requirements and Pre-Analytical Protocol
Fasting Requirement: Classic teaching (and most board items) specifies a 9 to 12-hour overnight fast for the lipid profile. Total cholesterol changes little after a meal, but triglycerides and calculated LDL-C are distorted by dietary chylomicrons. Current cardiovascular guidelines accept non-fasting profiles for routine screening and call for a fasting repeat when non-fasting triglycerides exceed about 400 mg/dL 400\text{ mg/dL} 400 mg/dL .
Posture & Tourniquet: Prolonged tourniquet application ( > 1 minute > 1\text{ minute} > 1 minute ) or transitioning from a recumbent to an upright seated position causes intravascular hemoconcentration of large non-diffusible lipoprotein macromolecules, falsely increasing cholesterol and triglyceride concentrations by 10 % to 15 % 10\%\text{ to }15\% 10% to 15% . Venipuncture should occur after the patient has been seated quietly for 5 minutes.
Serum vs. Plasma: Serum is the primary clinical specimen. If EDTA anticoagulated plasma is utilized, osmotic shifts draw water from erythrocytes into plasma, diluting large lipoproteins and causing measured values to be approximately 3 % 3\% 3% lower than corresponding serum values (a conversion factor of 1.03 1.03 1.03 is applied).
6. The Friedewald Formula and Methodological Boundaries
Historically, direct quantification of LDL cholesterol required preparative ultracentrifugation (beta-quantification). The Friedewald calculation was developed to estimate LDL-C from routine lipid profile components:
Total Cholesterol = HDL-C + LDL-C + VLDL-C \text{Total Cholesterol} = \text{HDL-C} + \text{LDL-C} + \text{VLDL-C} Total Cholesterol = HDL-C + LDL-C + VLDL-C
Assuming that in the fasting state, plasma VLDL contains a relatively constant triglyceride-to-cholesterol ratio of 5 : 1 5:1 5 : 1 by weight:
VLDL-C = Triglycerides 5 ( in mg/dL ) \text{VLDL-C} = \frac{\text{Triglycerides}}{5} \quad (\text{in mg/dL}) VLDL-C = 5 Triglycerides ( in mg/dL )
LDL-C = Total Cholesterol − HDL-C − Triglycerides 5 ( in mg/dL ) \text{LDL-C} = \text{Total Cholesterol} - \text{HDL-C} - \frac{\text{Triglycerides}}{5} \quad (\text{in mg/dL}) LDL-C = Total Cholesterol − HDL-C − 5 Triglycerides ( in mg/dL )
In SI units ( mmol/L \text{mmol/L} mmol/L ), the formula utilizes a denominator of 2.22 2.22 2.22 :
LDL-C = Total Cholesterol − HDL-C − Triglycerides 2.22 ( in mmol/L ) \text{LDL-C} = \text{Total Cholesterol} - \text{HDL-C} - \frac{\text{Triglycerides}}{2.22} \quad (\text{in mmol/L}) LDL-C = Total Cholesterol − HDL-C − 2.22 Triglycerides ( in mmol/L )
Caution
Mandatory Invalidating Criteria for the Friedewald Formula:
Serum Triglycerides > 400 mg/dL > 400\text{ mg/dL} > 400 mg/dL ( > 4.52 mmol/L > 4.52\text{ mmol/L} > 4.52 mmol/L ): The constant 5 : 1 5:1 5 : 1 ratio of triglycerides to cholesterol in VLDL collapses due to altered core lipid packaging, causing severe mathematical underestimation of LDL-C.
Presence of Chylomicrons: Non-fasting specimens or Type I/V dyslipidemias contain chylomicrons carrying exogenous triglycerides without conforming to VLDL stoichiometry.
Dysbetalipoproteinemia (Type III Hyperlipidemia): The accumulation of cholesterol-rich β \beta β -VLDL and IDL invalidates the standard ratio.
When Friedewald criteria are invalidated, clinical laboratories must measure LDL-C directly using homogeneous enzymatic clearance assays (employing selective detergents to mask non-LDL particles) or reference beta-quantification .
7. NCEP ATP III Clinical Reference Cutoffs
Lipid Parameter Desirable / Optimal Borderline High High / Undesirable Critical Alert Value
Total Cholesterol < 200 mg/dL < 200\text{ mg/dL} < 200 mg/dL ( < 5.18 mmol/L < 5.18\text{ mmol/L} < 5.18 mmol/L ) 200 − 239 mg/dL 200 - 239\text{ mg/dL} 200 − 239 mg/dL ≥ 240 mg/dL \ge 240\text{ mg/dL} ≥ 240 mg/dL ( ≥ 6.22 mmol/L \ge 6.22\text{ mmol/L} ≥ 6.22 mmol/L ) ---
LDL Cholesterol < 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL ( < 2.59 mmol/L < 2.59\text{ mmol/L} < 2.59 mmol/L ); near optimal 100 − 129 mg/dL 100 - 129\text{ mg/dL} 100 − 129 mg/dL 130 − 159 mg/dL 130 - 159\text{ mg/dL} 130 − 159 mg/dL ≥ 160 mg/dL \ge 160\text{ mg/dL} ≥ 160 mg/dL ( ≥ 190 \ge 190 ≥ 190 very high) ---
HDL Cholesterol ≥ 60 mg/dL \ge 60\text{ mg/dL} ≥ 60 mg/dL (Cardioprotective) 40 − 59 mg/dL 40 - 59\text{ mg/dL} 40 − 59 mg/dL < 40 mg/dL < 40\text{ mg/dL} < 40 mg/dL (Men); < 50 mg/dL < 50\text{ mg/dL} < 50 mg/dL (Women) ---
Triglycerides < 150 mg/dL < 150\text{ mg/dL} < 150 mg/dL ( < 1.70 mmol/L < 1.70\text{ mmol/L} < 1.70 mmol/L ) 150 − 199 mg/dL 150 - 199\text{ mg/dL} 150 − 199 mg/dL 200 − 499 mg/dL 200 - 499\text{ mg/dL} 200 − 499 mg/dL (very high: ≥ 500 mg/dL \ge 500\text{ mg/dL} ≥ 500 mg/dL ) ≥ 1000 mg/dL \ge 1000\text{ mg/dL} ≥ 1000 mg/dL Risk of Pancreatitis
Warning
Critical Panic Value: Serum triglycerides exceeding 1000 mg/dL 1000\text{ mg/dL} 1000 mg/dL ( 11.3 mmol/L 11.3\text{ mmol/L} 11.3 mmol/L ) present an acute, life-threatening risk of acute necrotizing pancreatitis . In pancreatic capillaries, excess triglycerides are hydrolyzed by escaping pancreatic lipase into massive quantities of free fatty acids, inducing capillary thrombosis, ischemia, and parenchymal necrosis.
8. Fredrickson Classification of Dyslipidemias
Type I (Familial Hyperchylomicronemia): Inactivating mutations in the Lipoprotein Lipase (LPL) or Apo C-II genes. Marked accumulation of chylomicrons. Standing plasma shows a thick creamy top layer over a crystal-clear infranate . Manifests with eruptive xanthomas, hepatosplenomegaly, and recurrent acute pancreatitis, without accelerated atherosclerosis.
Type IIa (Familial Hypercholesterolemia): Autosomal dominant mutations in the LDL receptor gene (or Apo B-100 / PCSK9 gain of function). Elevated LDL with normal VLDL. Standing plasma is completely clear . Clinically marked by severe premature coronary artery disease, tendon xanthomas (Achilles tendon), and xanthelasma.
Type IIb (Familial Combined Hyperlipidemia): Overproduction of hepatic Apo B-100. Concomitant elevation of LDL and VLDL . Standing plasma is clear to slightly hazy. High coronary risk.
Type III (Familial Dysbetalipoproteinemia / Broad-Beta Disease): Homozygosity for Apo E2/E2 , preventing normal hepatic receptor-mediated clearance of chylomicron remnants and IDL. Characterized by accumulating IDL and β \beta β -VLDL . Standing plasma is turbid, occasionally with a faint cream layer. Pathognomonic physical findings include palmar xanthomas (xanthoma striatum palmare) and tuberoeruptive xanthomas.
Type IV (Familial Hypertriglyceridemia): Increased hepatic secretion of VLDL with delayed catabolism. Standing plasma is turbid / milky throughout with no floating cream layer . Strongly associated with obesity, insulin resistance, and type 2 diabetes.
Type V (Mixed Hyperlipidemia): Combined elevation of chylomicrons and VLDL . Standing plasma demonstrates a floating creamy top layer over a turbid infranate . High risk of acute pancreatitis.